Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
about
Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight LossBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsGlucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Non-alcoholic fatty liver disease following liver transplantation: a clinical review.Emerging and future therapies for nonalcoholic steatohepatitis in adults.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.CC Chemokine Receptor 2 Promotes Recruitment of Myeloid Cells Associated with Insulin Resistance in Non-Alcoholic Fatty Liver Disease.
P2860
Q26775632-B3F84B53-696B-4AB6-AE9A-8CBB4F4AA37EQ26992979-11AD3733-C6FE-4275-97EC-4FDAE332BB10Q27021870-F5758C20-3E4E-430A-9BB4-B1820A9DC14BQ31149434-DC564737-5859-4008-9ACB-9D2CB721B481Q36406821-9C93D307-F9D2-4F40-A98C-92AD28528575Q36465496-B53FAE12-D9E7-4FFC-B540-B96BEA75D5E3Q38199526-23B23EAB-E5CC-4447-A11B-3F84C3650587Q38236774-DE6453E2-6D9F-4862-8A65-4AB8A05F7BE7Q38543105-5E8016B3-D4EA-40C1-AFE2-D5AF15EAD532Q38827586-22D1078D-A676-4DCC-8081-757E577370DBQ47779219-CA49EC46-ED02-4D1A-911C-3B22BA051403Q50116449-8D512279-406E-476D-8A4E-E8CEF3A80B83
P2860
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Liraglutide efficacy and actio ...... , randomised, controlled trial
@ast
Liraglutide efficacy and actio ...... , randomised, controlled trial
@en
Liraglutide efficacy and actio ...... , randomised, controlled trial
@nl
type
label
Liraglutide efficacy and actio ...... , randomised, controlled trial
@ast
Liraglutide efficacy and actio ...... , randomised, controlled trial
@en
Liraglutide efficacy and actio ...... , randomised, controlled trial
@nl
prefLabel
Liraglutide efficacy and actio ...... , randomised, controlled trial
@ast
Liraglutide efficacy and actio ...... , randomised, controlled trial
@en
Liraglutide efficacy and actio ...... , randomised, controlled trial
@nl
P2093
P2860
P50
P921
P1433
P1476
Liraglutide efficacy and actio ...... , randomised, controlled trial
@en
P2093
Deborah Stocken
Diana Hull
Piers Gaunt
Rachel M Brown
Stefan G Hübscher
Stephen C L Gough
P2860
P304
P356
10.1136/BMJOPEN-2013-003995
P407
P577
2013-11-04T00:00:00Z